OncoMatch/Clinical Trials/NCT05268172
IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites
Is NCT05268172 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies IFN-γ and CIK cells, Tcm cells or CAR T cells for pleural effusion, malignant.
Treatment: IFN-γ and CIK cells, Tcm cells or CAR T cells — The purpose of this study was to evaluate the efficacy of IFN- Y combined with T cells in the treatment of refractory malignant pleural effusion and acties, using a multicenter, single-arm, open design.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Cannot have received: other investigational drug
Participated in clinical trials of other drugs within four weeks
Lab requirements
Blood counts
Hemoglobin ≥ 90 g/L (no blood transfusion within 14 days); Neutrophil count > 1.5×10^9/L; Platelet count ≥ 90×10^9/L
Kidney function
Endogenous creatinine clearance ≥ 60 mL /min (Cockcroft-Gault formula)
Liver function
Total bilirubin ≤ 1.5×ULN; ALT or AST ≤ 2.5×ULN; ALT or AST ≤ 5×ULN if liver metastasis was present
Cardiac function
left ventricular ejection fraction (LVEF) ≥ 50%
Good function of major organs ... (1)Routine blood test: 1)Hemoglobin ≥ 90 g/L (no blood transfusion within 14 days); 2)Neutrophil count > 1.5×109/L; 3)Platelet count ≥ 90×109/L; (2)Biochemical examination: 1)Total bilirubin ≤ 1.5×ULN (upper limit of normal value); 2)Serum alanine aminotransferase (ALT) or AST ≤ 2.5×ULN; ALT or AST ≤ 5×ULN if liver metastasis was present; 3)Endogenous creatinine clearance ≥ 60 mL /min (Cockcroft-Gault formula); (3)Cardiac Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify